{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:59:08Z","timestamp":1790348348336,"version":"4.1.0"},"reference-count":70,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009068","name":"University of Bern","doi-asserted-by":"publisher","award":["Internal grant funding of Prof. Segelov"],"award-info":[{"award-number":["Internal grant funding of Prof. Segelov"]}],"id":[{"id":"10.13039\/100009068","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Echosens, France","award":["Loan of Fibroscan F430"],"award-info":[{"award-number":["Loan of Fibroscan F430"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,9,8]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic inflammation links cancer aetiologically to other diseases; therefore many cancer survivors live with long-term effects and comorbidities. While it becomes common place to outline long-term care in survivorship plans, liver health is often overlooked, with potential underdiagnosis of metabolic-dysfunction-associated steatotic liver disease (MASLD). Detecting early signs of MASLD is crucial, with new therapeutics able to prevent and even reverse liver damage. There is a need to understand its prevalence in cancer survivors, which is now possible with non-invasive tools such as vibration-controlled transient elastography (VCTE), which makes screening viable. Therefore, our study aims to address whether cancer survivors constitute a high-risk population for MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The EVALUATE Study is an observational, single-centre, cross-sectional study co-designed with patient and public involvement. It aims to assess the prevalence of fibrotic MASLD (fMASLD) and precursor conditions (non-fibrotic MASLD and steatotic liver disease) among 200 participants who were diagnosed with breast cancer or colorectal cancer 5\u201310 years ago, without recurrence. Participants\u2019 risk of fMASLD will be determined using VCTE and blood-based biomarkers. A subset with indeterminate risk will also undergo MRI of the liver. Data will be analysed using logistic regression (univariable and multivariable) to examine patient-related, tumour-related and treatment-related risk factors for fMASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study involves human participants and was approved by the Cantonal Ethics Committee of Bern (2025-00890). Participants gave informed consent to participate in the study before taking part. The results will be communicated through peer-reviewed publications and academic conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT07280143\">NCT07280143<\/jats:ext-link>\n                      \/DRKS00038398\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-119603","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:05:42Z","timestamp":1790345142000},"page":"e119603","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Development of MASLD among survivors of breast or colorectal cancer (EVALUATE): protocol for a single-centre observational cross-sectional study"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct07280143","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6636-9818","authenticated-orcid":false,"given":"Dani\u00eblle","family":"Verschoor","sequence":"first","affiliation":[{"name":"Department of Clinical Research (DCR), University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian","family":"H\u00e4fele","sequence":"additional","affiliation":[{"name":"Department of Clinical Research (DCR), University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogo E","family":"Oramalu","sequence":"additional","affiliation":[{"name":"Department of Clinical Research (DCR), University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Berzigotti","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery and Medicine, Inselspital Universitatsspital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M","family":"Aebersold","sequence":"additional","affiliation":[{"name":"Department Radiation Oncology, University Comprehensive Cancer Centre, Inselspital Universitatsspital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Bastiaansen","sequence":"additional","affiliation":[{"name":"Translational Imaging Center (TIC), Swiss Institute for Translational and Entrepreneurial Medicine, Bern, Switzerland"},{"name":"Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital Universitatsspital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Catucci","sequence":"additional","affiliation":[{"name":"Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital Universitatsspital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian T","family":"Huber","sequence":"additional","affiliation":[{"name":"Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital Universitatsspital Bern, Bern, Switzerland"},{"name":"Department of Radiology and Nuclear Medicine, Luzerner Kantonsspital, Lucerne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin V","family":"Ineichen","sequence":"additional","affiliation":[{"name":"Medical Data Science, Department of Clinical Research, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kohler","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery and Medicine, Inselspital Universitatsspital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital Universitatsspital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Segelov","sequence":"additional","affiliation":[{"name":"Department of Clinical Research (DCR), University of Bern, Bern, Switzerland"},{"name":"Department Radiation Oncology, University Comprehensive Cancer Centre, Inselspital Universitatsspital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2026092507052495000_16.9.e119603.1","unstructured":"World Health Organization . Global cancer burden growing, amidst mounting need for services. 2024. Available: https:\/\/www.who.int\/news\/item\/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services [Accessed 17 Aug 2024]."},{"key":"2026092507052495000_16.9.e119603.2","unstructured":"Nationale Strategie gegen Krebs 2014\u20132020. 2018. Available: https:\/\/www.bag.admin.ch\/bag\/de\/home\/strategie-und-politik\/nationale-gesundheitsstrategien\/nationale-strategie-gegen-krebs-2014-2017.html [Accessed 17 Aug 2024]."},{"key":"2026092507052495000_16.9.e119603.3","unstructured":"Cancer Today. 2024. Available: https:\/\/gco.iarc.fr\/today\/en\/dataviz\/pie?mode=cancer&group_populations=1 [Accessed 17 Aug 2024]."},{"key":"2026092507052495000_16.9.e119603.4","unstructured":"Cancer Facts &amp; Figures 2025. Available: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2025-cancer-facts-figures.html [Accessed 26 Nov 2025]."},{"key":"2026092507052495000_16.9.e119603.5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"2026092507052495000_16.9.e119603.6","doi-asserted-by":"publisher","DOI":"10.1038\/nature01322"},{"key":"2026092507052495000_16.9.e119603.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2010.09.006"},{"key":"2026092507052495000_16.9.e119603.8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jaccao.2022.03.005","article-title":"Cardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Zullig","year":"2022","journal-title":"JACC CardioOncology"},{"key":"2026092507052495000_16.9.e119603.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0126-x"},{"key":"2026092507052495000_16.9.e119603.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0409"},{"key":"2026092507052495000_16.9.e119603.11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.699.699","article-title":"Diabetes, Hypertension and Cardiovascular Events in Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study","volume":"106","author":"Baker","year":"2005","journal-title":"Blood"},{"key":"2026092507052495000_16.9.e119603.12","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000394"},{"key":"2026092507052495000_16.9.e119603.13","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/2047487320905722","article-title":"Status of dyslipidemia management and statin undertreatment in Korean cancer survivors: A Korean National Health and Nutrition Examination Survey study","volume":"28","author":"Shin","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026092507052495000_16.9.e119603.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05686-5"},{"key":"2026092507052495000_16.9.e119603.15","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-020-0707-5","article-title":"Cancer-Related Fatigue: Causes and Current Treatment Options","volume":"21","author":"Thong","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"2026092507052495000_16.9.e119603.16","doi-asserted-by":"crossref","first-page":"880","DOI":"10.62347\/NWHM4133","article-title":"Prevalence of multimorbidity in survivors of 28 cancer sites: an English nationwide cross-sectional study","volume":"14","author":"Ahmad","year":"2024","journal-title":"Am J Cancer Res"},{"key":"2026092507052495000_16.9.e119603.17","doi-asserted-by":"crossref","unstructured":"Petrova D , Catena A , Rodriguez-Barranco M , et al . Physical Comorbidities and Depression in Recent and Long-Term Adult Cancer Survivors: NHANES 2007-2018. Cancers Basel 2021. doi:10.3390\/cancers13133368","DOI":"10.3390\/cancers13133368"},{"key":"2026092507052495000_16.9.e119603.18","doi-asserted-by":"publisher","DOI":"10.2190\/PM.40.2.c"},{"key":"2026092507052495000_16.9.e119603.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1941"},{"key":"2026092507052495000_16.9.e119603.20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/OP.23.00716","article-title":"Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations","volume":"20","author":"Hart","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"2026092507052495000_16.9.e119603.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.3809"},{"key":"2026092507052495000_16.9.e119603.22","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2019.20152","article-title":"Nonalcoholic fatty liver disease burden \u2013 Switzerland 2018\u20132030","volume":"149","author":"Goossens","year":"2019","journal-title":"Swiss Med Wkly"},{"key":"2026092507052495000_16.9.e119603.23","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.jhep.2024.07.026","article-title":"High prevalence of steatotic liver disease and fibrosis in the general population: A large prospective study in China","volume":"82","author":"Liu","year":"2025","journal-title":"J Hepatol"},{"key":"2026092507052495000_16.9.e119603.24","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/HEP.0000000000001211","article-title":"Prevalence of metabolic dysfunction\u2013associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data","volume":"82","author":"Unalp-Arida","year":"2025","journal-title":"Hepatology"},{"key":"2026092507052495000_16.9.e119603.25","doi-asserted-by":"crossref","first-page":"100185","DOI":"10.1016\/j.esmoop.2021.100185","article-title":"Cancer and hepatic steatosis","volume":"6","author":"Paternostro","year":"2021","journal-title":"ESMO Open"},{"key":"2026092507052495000_16.9.e119603.26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30251"},{"key":"2026092507052495000_16.9.e119603.27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29085"},{"key":"2026092507052495000_16.9.e119603.28","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(23)02021-4","article-title":"Standardized non-invasive screening for non-alcoholic fatty liver disease in people with type 2 diabetes identifies a substantial number of individuals with advanced liver disease","volume":"78","author":"Lange","year":"2023","journal-title":"J Hepatol"},{"key":"2026092507052495000_16.9.e119603.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039"},{"key":"2026092507052495000_16.9.e119603.30","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-07089-w"},{"key":"2026092507052495000_16.9.e119603.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031"},{"key":"2026092507052495000_16.9.e119603.32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026092507052495000_16.9.e119603.33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.042"},{"key":"2026092507052495000_16.9.e119603.34","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000055","article-title":"Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores","volume":"7","author":"Noureddin","year":"2023","journal-title":"Hepatol Commun"},{"key":"2026092507052495000_16.9.e119603.35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J Hepatol"},{"key":"2026092507052495000_16.9.e119603.36","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/HEP.0000000000000417","article-title":"Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH","volume":"78","author":"Li","year":"2023","journal-title":"Hepatology"},{"key":"2026092507052495000_16.9.e119603.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"2026092507052495000_16.9.e119603.38","unstructured":"Commissioner O of the FDA . Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. FDA; 2024. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease [Accessed 26 Nov 2025]."},{"key":"2026092507052495000_16.9.e119603.39","unstructured":"Madrigal Pharmaceuticals Announces FDA Approval of RezdiffraTM (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis | Madrigal Pharmaceuticals, Inc. Available: https:\/\/ir.madrigalpharma.com\/news-releases\/news-release-details\/madrigal-pharmaceuticals-announces-fda-approval-rezdiffratm [Accessed 26 Nov 2025]."},{"key":"2026092507052495000_16.9.e119603.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258"},{"key":"2026092507052495000_16.9.e119603.41","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026092507052495000_16.9.e119603.42","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1097\/CM9.0000000000002121","article-title":"Prevalence of hepatic steatosis and metabolic associated fatty liver disease among female breast cancer survivors","volume":"135","author":"Tian","year":"2022","journal-title":"Chin Med J"},{"key":"2026092507052495000_16.9.e119603.43","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017277","article-title":"Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery","volume":"98","author":"Lee","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2026092507052495000_16.9.e119603.44","doi-asserted-by":"crossref","first-page":"100461","DOI":"10.1016\/j.currproblcancer.2019.01.002","article-title":"Hepatosteatosis may predict late recurrence of breast cancer: A single-center observational study","volume":"43","author":"Kus","year":"2019","journal-title":"Curr Probl Cancer"},{"key":"2026092507052495000_16.9.e119603.45","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0370"},{"key":"2026092507052495000_16.9.e119603.46","first-page":"184","article-title":"Poster 1701: Aromatase Inhibitors and Nonalcoholic Fatty Liver Disease in Early Stage Breast Cancer Women","volume":"68","author":"Lee","year":"2018","journal-title":"Hepatology"},{"key":"2026092507052495000_16.9.e119603.47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4048\/jbc.2021.24.e41","article-title":"Fatty Liver in Hormone Receptor-Positive Breast Cancer and Its Impact on Patient\u2019s Survival","volume":"24","author":"Taroeno-Hariadi","year":"2021","journal-title":"J Breast Cancer"},{"key":"2026092507052495000_16.9.e119603.48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-3239"},{"key":"2026092507052495000_16.9.e119603.49","unstructured":"Cancer: number and rates of new cases and deaths by language region, cancer site, gender, period, and age class. PX-Web. Available: https:\/\/www.pxweb.bfs.admin.ch\/pxweb\/en\/px-x-1403030300_161\/px-x-1403030300_161\/px-x-1403030300_161.px\/table\/tableViewLayout2\/ [Accessed 5 Sep 2025]."},{"key":"2026092507052495000_16.9.e119603.50","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/00365521.2019.1629007","article-title":"Transient liver elastography in normal pregnancy - a longitudinal cohort study","volume":"54","author":"Stenberg Ribeiro","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"2026092507052495000_16.9.e119603.51","unstructured":"Verschoor D . BioRender. Creat. BioRender; 2026. Available: https:\/\/BioRender.com\/pdq69kb"},{"key":"2026092507052495000_16.9.e119603.52","doi-asserted-by":"publisher","DOI":"10.1249\/01.MSS.0000078924.61453.FB"},{"key":"2026092507052495000_16.9.e119603.53","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2891-9-36","article-title":"Relative validation of a food frequency questionnaire for national health and nutrition monitoring","volume":"9","author":"Haftenberger","year":"2010","journal-title":"Nutr J"},{"key":"2026092507052495000_16.9.e119603.54","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.469"},{"key":"2026092507052495000_16.9.e119603.55","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00448-8"},{"key":"2026092507052495000_16.9.e119603.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.10.034"},{"key":"2026092507052495000_16.9.e119603.57","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.cgh.2023.02.003","article-title":"MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death","volume":"21","author":"Truong","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092507052495000_16.9.e119603.58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jhep.2024.03.023","article-title":"Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes","volume":"81","author":"Castera","year":"2024","journal-title":"J Hepatol"},{"key":"2026092507052495000_16.9.e119603.59","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jhep.2022.07.020","article-title":"Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD","volume":"77","author":"Kim","year":"2022","journal-title":"J Hepatol"},{"key":"2026092507052495000_16.9.e119603.60","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(23)01412-5","article-title":"Screening for advanced liver disease in the general population","volume":"402","author":"Tapper","year":"2023","journal-title":"The Lancet"},{"key":"2026092507052495000_16.9.e119603.61","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.86.2.420"},{"key":"2026092507052495000_16.9.e119603.62","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(86)90837-8"},{"key":"2026092507052495000_16.9.e119603.63","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canep.2017.04.007","article-title":"Nonalcoholic fatty liver disease and mortality among cancer survivors","volume":"48","author":"Brown","year":"2017","journal-title":"Cancer Epidemiol"},{"key":"2026092507052495000_16.9.e119603.64","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000000500"},{"key":"2026092507052495000_16.9.e119603.65","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1177\/1076029616665925","article-title":"Association of Nonalcoholic Fatty Liver Disease and Venous Thromboembolism in Women With Endometrial Cancer","volume":"23","author":"Moeini","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026092507052495000_16.9.e119603.66","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2217\/fon-2019-0634","article-title":"Recurrence pattern in the presence of hepatosteatosis in breast cancer: does it facilitate liver metastasis","volume":"16","author":"Kus","year":"2020","journal-title":"Future Oncol"},{"key":"2026092507052495000_16.9.e119603.67","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.clbc.2016.12.004","article-title":"The Relationship Between Tamoxifen-associated Nonalcoholic Fatty Liver Disease and the Prognosis of Patients With Early-stage Breast Cancer","volume":"17","author":"Yan","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"2026092507052495000_16.9.e119603.68","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jfma.2015.05.006","article-title":"Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients","volume":"115","author":"Pan","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"2026092507052495000_16.9.e119603.69","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4166\/kjg.2022.113","article-title":"Risk of Metabolic Syndrome and Fatty Liver Diseases in Gastric Cancer Survivors: A Propensity Score-Matched Analysis","volume":"81","author":"Han","year":"2023","journal-title":"Korean J Gastroenterol"},{"key":"2026092507052495000_16.9.e119603.70","doi-asserted-by":"crossref","first-page":"S767","DOI":"10.1016\/S0168-8278(22)01851-7","article-title":"Abstract 2521: A comparative analysis between incident versus baseline nonalcoholic fatty liver disease in breast cancer survivors from a prospective cohort","volume":"76","author":"Kim","year":"2022","journal-title":"Hepatology"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-119603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:05:51Z","timestamp":1790345151000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-119603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":70,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-119603"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-119603","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}